# Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.

> **NCT07730346** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanjing Zenshine Pharmaceuticals** · enrollment: 858 (estimated)

## Conditions studied

- Influenza Prevention

## Interventions

- **DRUG:** Sebaloxavir marboxil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07730346
- **Lead sponsor:** Nanjing Zenshine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-07
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-01-30
- **Target enrollment:** 858 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730346, "Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*